Inflammatory Bowel Disease Treatment Market worth $~32 billion by 2027
The report "Inflammatory Bowel Disease Treatment Market by Type (Crohn’s Disease, Ulcerative Colitis), Drug Class (TNF inhibitors, Corticosteroids, Aminosalicylates, JAK inhibitors, Anti-intergin, IL inhibitors, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), by Route of Administration (Oral, Injectable) and Region – Global Forecast to 2027", is projected to reach USD ~32 billion by 2027 from 24 billion in 2022, at a CAGR of 5% during the forecast period.
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/inflammatory-bowel-disease-treatment-market-9220307.html
The rising prevalence of Crohn’s disease and ulcerative disease across the globe is expected to drive growth over the forecast period. The increase adoption of biologics for the treatment and the presence of strong pipeline drugs is anticipated to boost the growth.
Crohn’s disease dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of more than 60% in 2021.
The segment is anticipated to maintain its dominance throughout the forecast period. High prevalence rate, increasing perception rate of biologics, and high cost associated with Crohn’s disease treatment are factors driving the market of inflammatory bowel disease treatment.
North America to command the highest market share for inflammatory bowel disease market.
The region is expected to experience lucrative growth over the forecast period. High treatment rates, increasing prescription of novel drugs, and better reimbursement policies in the region are the factors supporting market growth in this region.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Inflammatory Bowel Disease Treatment Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
